Lutetium Lu 177 dotatate
- Generic Name
- Lutetium Lu 177 dotatate
- Brand Names
- Lutathera
- Drug Type
- Small Molecule
- Chemical Formula
- C65H87LuN14O19S2
- CAS Number
- 437608-50-9
- Unique Ingredient Identifier
- AE221IM3BB
- Background
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-D...
- Indication
Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults .
- Associated Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Associated Therapies
- -
CABINET presents cabozantinib as a new treatment option for NETs
New CABINET trial data show cabozantinib's efficacy in advanced-stage neuroendocrine tumours (NETs) post-progression after 1–2 lines of systemic therapy. Patients with locally advanced or metastatic well or moderately differentiated extrapancreatic or pancreatic NETs were randomly assigned 2:1 to cabozantinib or placebo. Primary endpoint was progression-free survival (PFS).
Theranostics as a Driving Force in Nuclear Medicine
Theranostics, precision medicine using PET imaging to identify targets for therapy, has evolved rapidly in nuclear medicine. Examples include 18F-FGFR1 for FGFR1-expressing tumors, 89Zr-girentuximab for hypoxia imaging, and PSMA-targeted radiotracers for ccRCC. Clinical applications like PSMA-targeted theranostics in non-prostate cancers and individualized dosimetry with lutetium-177-labeled agents are discussed. The potential of digital twins for personalized dosing is also highlighted, emphasizing the need for continued research and technological advancements.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath